Chairman Tom Lee urges stockholders to vote YES to proposal #2 to support Bitmine’s goal of growing ETH per share Stockholders can find the latest information around voting YES and the Chairman’s message on the Bitmine website Bitmine staked ETH stands at 1,256,083 and MAVAN staking solution on track to launch Q1 2026 Bitmine remains […]
In this free webinar, gain insight into the antibody-drug conjugate (ADC) therapeutic landscape and pipeline. Attendees will be introduced to global site selection, preparedness and training required for successful ADC development. The featured speakers will discuss dose optimization and safety monitoring, including capturing long-term outcomes. Attendees will learn about incorporating the patient voice into protocol
In this free webinar, learn how recombinant insulin improves viral production across diverse vaccine platforms. Attendees will gain insight into the role of recombinant trypsin in efficient cell dissociation and improved virus infectivity and quality. The featured speakers will discuss how the implementation of recombinant insulin and trypsin enhances safety, improves efficiency and enables cost-effective
Accelerating AI-enabled acute-care diagnostics by years and millions of dollars — MeMed, the leader in host-response diagnostics, announced it has been awarded a competitive national grant through the IIA to establish an acute-care diagnostics and proteomics biobank, as part of a nationwide AI R&D data infrastructure. This initiative significantly accelerates the development and validation of
Company experiencing strong demand in the U.S. following FDA marketing authorization of ProSense® as the only on-label minimally invasive solution for the local treatment of low-risk breast cancer, addressing a market opportunity of approximately 200,000 patients Record European sales, driven by positive effects of U.S. clearance and continued growing adoption of ProSense® cryoablation for breast
Showcasing a complete hardware and software product portfolio ecosystem designed to adapt to diverse environments and needs Promethean, a global education and workplace technology company and a brand of Mynd.ai (NYSE American: MYND), today announced its participation in major international trade shows taking place January through March 2026. At these events, Promethean will demonstrate its
Vision Marine Technologies Inc. (NASDAQ: VMAR), today announced that the Company’s board of directors (the “Board”) approved 1 for 40 reverse stock split of the Company’s common shares. The reverse stock split is expected to become effective when the market opens on January 14, 2026 (the “Effective Date”) and the Company’s common shares will begin
New research shows Republican hostility to EVs easing, end of federal EV subsidies curbing EV demand, strong EV sales potential in multifamily housing, 49 percent of younger (under 45) open to buying Chinese-made vehicles, and sharply polarized views of Elon Musk and Tesla. President Trump remains controversial among auto consumers, with only 28 percent rating
(NASDAQ:ACHV), SEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that it has confirmed the promotion of Mark Rubinstein, M.D., from Interim Chief
Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer Experienced medical executive advances to permanent role following successful leadership as Interim CMO GlobeNewswire January 12, 2026 SEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the